Laprophan IPO in Morocco raises $1.5 billion for expansion
What happened
Laprophan completed its initial public offering in Morocco, which was seven times oversubscribed. Investors submitted orders worth $1.5 billion for an offer seeking to raise 2.22 billion dirhams. The IPO, which is the largest listing on the Casablanca Stock Exchange this year, aims to support expansion and the acquisition of Polymedic.
Why it matters
The successful offering reflects strong investor demand for Laprophan. The funds are intended to support expansion plans, including the acquisition of Polymedic. Laprophan reported 2025 revenue of $180 million, an increase from the previous year.
Who's involved
- LaprophanPharmaceutical company that conducted the IPO and operates sites in Morocco and Switzerland.
- MoroccoSovereign state where the IPO took place and where Laprophan operates industrial sites.
- SwitzerlandCountry where Laprophan operates industrial sites.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
Keep exploring
The entities involved
- Laprophan
-
Morocco
sovereign state in North Africa
-
Switzerland
country in Central Europe